Predicting the Response to Immunotherapy Using Artificial Intelligence
A study published in The Lancet Oncology establishes for the first
time that artificial intelligence can process medical images to extract
biological and clinical information. By designing an algorithm and
developing it to analyse CT scan images, medical researchers at Gustave
Roussy, CentraleSupélec, Inserm, Paris-Sud University and TheraPanacea
(spin-off from CentraleSupélec specialising in artificial intelligence
in oncology-radiotherapy and precision medicine) have created a
so-called radiomic signature. This signature defines the level of
lymphocyte infiltration of a tumour and provides a predictive score for
the efficacy of immunotherapy in the patient.
In the future, physicians might thus be able to use imaging to identify biological phenomena in a tumour located in any part of the body without having to perform a biopsy.
Up to now, no marker can accurately identify those patients who will respond to anti-PD-1/PD-L1 immunotherapy in a situation where only 15 to 30% of patients do respond to such treatment. It is known that the richer the tumour environment is immunologically (presence of lymphocytes) the greater the chance that immunotherapy will be effective, so the researchers have tried to characterise this environment using imaging and correlate this with the patients’ clinical response. Such is the objective of the radiomic signature designed and validated in the study published in The Lancet Oncology.
In this retrospective study, the radiomic signature was captured, developed and validated in 500 patients with solid tumours (all sites) from four independent cohorts. It was validated genomically, histologically and clinically, making it particularly robust.
Using an approach based on machine learning, the team first taught the algorithm to use relevant information extracted from CT scans of patients participating in the MOSCATO study1 , which also held tumor genome data. Thus, based solely on images, the algorithm learned to predict what the genome might have revealed about the tumour immune infiltrate, in particular with respect to the presence of cytotoxic T-lymphocytes (CD8) in the tumour, and it established a radiomic signature.
This signature was tested and validated in other cohorts including that of TCGA (The Cancer Genome Atlas) thus showing that imaging could predict a biological phenomenon, providing an estimation of the degree of immune infiltration of a tumour.
Then, to test the applicability of this signature in a real situation and correlate it to the efficacy of immunotherapy, it was evaluated using CT scans performed before the start of treatment in patients participating in 5 phase I trials of anti-PD-1/PD-L1 immunotherapy. It was found that the patients in whom immunotherapy was effective at 3 and 6 months had higher radiomic scores as did those with better overall survival.
The next clinical study will assess the signature both retrospectively and prospectively, will use larger numbers of patients and will stratify them according to cancer type in order to refine the signature.
This will also employ more sophisticated automatic learning and artificial intelligence algorithms to predict patient response to immunotherapy. To that end, the researchers are intending to integrate data from imaging, molecular biology and tissue analysis. This is the objective of the collaboration between Gustave Roussy, Inserm, Université Paris-Sud, CentraleSupélec and TheraPanacea to identify those patients who are the most likely to respond to treatment, thus improving the efficacy/cost ratio of the treatment.
// About radiomics
In radiomics, it is considered that imaging (CT, MRI, ultrasound, etc.) not only reveals the organisation and architecture of tissues but also their molecular or cellular composition. The technique involves the use of algorithms to analyse a medical image objectively in order to extract from it information which is invisible to the naked eye, such as the texture of a tumour, its micro-environment, its heterogeneity, etc. For the patient this represents a non-invasive approach that can be repeated over the course of the disease to follow its progress.
DOI : 10.1016/S1470-2045(18)30413-3
1 Results of the MOSCATO study published in Cancer Discovery : http://cancerdiscovery.aacrjournals.org/content/early/2017/03/26/2159-8290.CD-16-1396
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
CA-VEEVA-SYSTEMS-INC.19.6.2019 13:21:13 CEST | Pressemeddelelse
New Survey Finds Fragmented Processes and System Silos Slowing Clinical Trials
CA-ANDERSEN-TAX19.6.2019 13:11:12 CEST | Pressemeddelelse
Andersen-navnet i fremgang i Polen
FL-VIRGIN-VOYAGES19.6.2019 13:02:11 CEST | Pressemeddelelse
Geri Horner Test Drives RockStar Suites aboard Virgin Voyages’ Scarlet Lady
CT-BEQOM19.6.2019 13:02:11 CEST | Pressemeddelelse
beqom Study Shows U.S., UK Employees Aware of Gender Wage Gaps but Not of Actions Taken by Employers or Governments to Close Them
VA-HILTON19.6.2019 12:07:06 CEST | Pressemeddelelse
Moon-Walking Mini-Breaks, 3D-Printed Room Service and Hyper-Personalised Spaces: Welcome to the Hotel of 2119
CA-INVIVOSCRIBE19.6.2019 12:02:06 CEST | Pressemeddelelse
Japan’s MHLW Approves Invivoscribe’s LeukoStrat CDx FLT3 Mutation Assay as the CDx for Daiichi Sankyo’s Quizartinib for Treatment of Relapsed/Refractory FLT3-ITD AML. Expands Use to Include Specimens Collected in EDTA
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum